|
|
|
|
| LEADER |
01751nam a22003135i 4500 |
| 001 |
000284222 |
| 005 |
20211119093618.0 |
| 007 |
cr nn 008mamaa |
| 008 |
100301s2008 xxu| s |||| 0|eng d |
| 020 |
|
|
|a 9780387758411
|
| 024 |
7 |
|
|a 10.1007/978-0-387-75841-1
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a Immunogenicity of Biopharmaceuticals /
|c edited by Marco Weert, Eva Horn Møller.
|
| 250 |
|
|
|a 1st ed. 2008.
|
| 260 |
# |
# |
|a New York, NY :
|b Springer New York :
|b Imprint: Springer,
|c 2008.
|
| 300 |
|
|
|a XII, 266 p. :
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Biotechnology: Pharmaceutical Aspects ;
|v VIII
|
| 505 |
0 |
|
|a Immune Reactions Towards Biopharmaceuticals – a General, Mechanistic Overview -- Clinical Aspects of Immunogenicity to Biopharmaceuticals -- Assessment of Unwanted Immunogenicity -- Models for Prediction of Immunogenicity -- Immunogenicity of Biopharmaceuticals: Causes, Methods to Reduce Immunogenicity, and Biosimilars -- Case Study: Immunogenicity of rhEPO -- Case Study: Immunogenicity of Interferon-Beta -- Case Study: Immunogenicity of Insulin -- Case Study: Immunogenicity of Factor VIII -- Case Study: Immunogenicity of Natalizumab -- Case Study: Immunogenicity of Anti-TNF Antibodies -- Heparin-Induced Thrombocytopenia -- Presenting an Immunogenicity Risk Assessment to Regulatory Agencies.
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
|
0 |
|a Immunology.
|
| 650 |
1 |
4 |
|a Pharmacology/Toxicology.
|
| 650 |
2 |
4 |
|a Immunology.
|
| 700 |
1 |
|
|a Weert, Marco.
|e editor.
|
| 700 |
1 |
|
|a Møller, Eva Horn.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|